The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
Open accessAbstract
Background: Obesity is an epidemiological issue that negatively affects public health and has led to a high global burden on the healthcare system. Several approaches to control and overcome the obesity crisis have been established. However, Nobel discoverers found that glucagon-like peptide-1 analogues (GLP-1 analogues) positively regulate appetite and food intake, eventually leading to weight loss. Objective: The present systematic review aims to summarize the currently available evidence of the impact of GLP-1 analogues on appetite, gastric emptying, taste sensitivity, and food preferences among adults with obesity without other chronic diseases. Methods: A systematic literature search was conducted from October 2021 to December 2021 from three electronic databases (PubMed, Scopus, and ScienceDirect), including only randomized clinical trials (RCTs). Studies were based on the use of GLP-1 analogues, of any dosage and duration among adults with obesity without other medical diseases; studies measured appetite, gastric emptying, food preferences, and taste as a primary or secondary outcome. The risk of publication bias in each study was assessed independently using the updated Cochrane risk-of-bias tool (RoB2). Results: Twelve studies met the inclusion criteria with a total sample size of 445 participants. All the included studies measured at least one or more of the primary outcomes. The promising effect was evidenced by most studies showing appetite suppression, delayed gastric emptying, and changes in taste and food preferences. Conclusion: GLP-1 analogues are effective obesity management therapy that could decrease food intake and eventually reduce weight by suppressing appetite, reducing hunger, decreasing gastric emptying, and altering food preferences and taste. However, high-quality, long-term, large sample size studies are crucial to examine the efficacy and effective dose of GLP-1 analogues intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This group of drugs slows the rate of post‐prandial gastric emptying [2, 3, 4]”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Appetite control: methodological aspects of the evaluation of foods
Blundell, J., De Graaf, C., Hulshof, T., Jebb, S., Livingstone, B., Lluch, A., Mela, D., Salah, S., Schuring, E., Van Der Knaap, H., et al. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00714.x · Cited by 1,007
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Stubbs, R. J., Hughes, D. A., Johnstone, A. M., Rowley, E., Reid, C., Elia, M., Stratton, R., Delargy, H., King, N., & Blundell, J. E. (2000) · British Journal Of Nutrition · doi:10.1017/s0007114500001719 · Cited by 674
Verdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 4×
“14).(26) Also, Saxena et al (2021) found that Liraglutide caused a significant delay in gastric emptying when administered over six weeks.”
BackgroundResultInfluentialEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · cited 6×
“09, respectively).(28) A crossover study by Näslund et al (2004) used two methods to administer GLP-1 for five days in a row for each intervention.”
BackgroundMethodResultInfluentialGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 19×
“…of fullness were not significantly different between GLP-1 infusion and placebo (saline infusion) (P = 0.4).27 The same results were found in the Flint et al 2001 study, which decreased the ratings of hunger and prospective food consumption decreased in the GLP-1 infusion compared with saline…”
BackgroundMethodResultInfluentialEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Verdich, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 336
Näslund, E., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 307
Althumiri, N. A., Basyouni, M. H., AlMousa, N., AlJuwaysim, M. F., Almubark, R. A., BinDhim, N. F., Alkhamaali, Z., & Alqahtani, S. A. (2021) · Healthcare · doi:10.3390/healthcare9030311 · Cited by 292
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245 · cited 9×
“Two studies out of eight used Liraglutide,24,26 four studies out of eight used GLP-1 infusion,16,20,27,28 and two studies Diabetes, Metabolic Syndrome and Obesity 2023:16 https://doi.org/10.2147/DMSO.S387116 DovePress 589 Dovepress Aldawsari et al Powered by TCPDF (www.tcpdf.org) out of eight used Semaglutide.22,23 Am…”
BackgroundResultInfluentialHalawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224
Weight Loss Strategies for Treatment of Obesity
Kushner, R. F. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.09.005 · Cited by 219
Peripheral Mechanisms in Appetite Regulation
Camilleri, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.016 · Cited by 214
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 2×
“GLP-1 analogues induce weight loss through multiple mechanistic properties, including insulin stimulation, inhibition of glucagon secretion, delaying gastric emptying, enhancing satiety, reducing hunger, reducing energy intake, and regulating appetite and food reward.(11,13,14) A multiplex brain-gut interaction orches…”
BackgroundResultAmerican Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 173
FDA-Approved Anti-Obesity Drugs in the United States
Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.009 · Cited by 170
Kadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166 · cited 10×
“A study by Kadouh et al (2020) measured the taste by standardized nutrient drink test; found a significant less desire for sweet, salty, fatty, and savory foods with Liraglutide when compared to placebo.17 A study by Flint et al 2001 assessed palatability using the ratings of palatability…”
BackgroundMethodResultInfluentialNäslund, E., King, N., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Hill, A. J., Rogers, P. J., & Blundell, J. E. (1995) · PubMed · Cited by 135
Stimulation of incretin secreting cells
Pais, R., Gribble, F. M., & Reimann, F. M. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815618177 · Cited by 115
Medhus, A. W., Lofthus, C. M., Bredesen, J. E., & Husebye, E. (2001) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2001.00249.x · Cited by 99
Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Acosta, A., Camilleri, M., Burton, D., O'Neill, J., Eckert, D., Carlson, P., & Zinsmeister, A. R. (2015) · Physiological Reports · doi:10.14814/phy2.12610 · Cited by 78
Tronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., Bakizada, Z. M., & Chao, A. M. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0348-6 · Cited by 74
Halawi, H., Camilleri, M., Acosta, A. J., Vázquez‐Roque, M. I., Oduyebo, I., Burton, D. D., Busciglio, I. A., & Zinsmeister, A. R. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2017 · Cited by 56
Ulrich, W. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 48
Saxena, A. R., Banerjee, A., Corbin, K. D., Parsons, S. A., & Smith, S. R. (2021) · Obesity Science & Practice · doi:10.1002/osp4.486 · Cited by 25
Trahair, L. G., Horowitz, M., Marathe, C. S., Lange, K., Standfield, S., Rayner, C. K., & Jones, K. L. (2014) · Physiological Reports · doi:10.14814/phy2.12204 · Cited by 22
Douglas, S. M., & Leidy, H. J. (2019) · Current Developments in Nutrition · doi:10.1093/cdn/nzz061 · Cited by 21
Kashima, N., Kimura, K., Nishitani, N., Endo, M. Y., Fukuba, Y., & Kashima, H. (2020) · Nutrients · doi:10.3390/nu12051249 · Cited by 17
Abdeen, G. N., Miras, A. D., Alqahtani, A. R., & le Roux, C. W. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.10.033 · Cited by 13
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-ad08b · Cited by 7
Research works printed but not linked: 4
- Van Bloemendaal, 2014, Diabetes, 2014, 1
- Kadouh, 2020, Cad Saude Publica, 12, 1
- Kamioka, 2019, Japanese Pharmacol Ther, 47, 1177
- Hill, 1995, Int J Obes Relat Metab Disord J Int Assoc Study Obes, 1995, 361
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Balasubramanian, R., Schneider, E., Gunnigle, E., Cotter, P. D., & Cryan, J. F. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105562 · Cited by 143
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“…pro-opiomelanocortin/cocaine-and amphetamine-stimulated transcription (POMC + /CART + ), resulting in satiety [35]. beneficial effect of GLP-1 RA therapy has been attributed to the modulatory action of central appetite control, which in caloric restriction and subsequent weight loss [33].”
Background
Metadata
- Authors
- Aldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M.
- Affiliations
- King Saud University (SA)
- Corresponding author
- Aldawsari, Malikah
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2023-03
- Volume
- Volume 16
- Pages
- 575-595
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC9987242
- OpenAlex
- W4322773858
- Semantic Scholar
- bfb01b3839e12cdd8d7b7f8b07656fbd58ec6987
- Cited by
- 115
- References
- 44
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 34 · 2023: 8
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- King Saud University
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, obesity, appetite suppression, gastric emptying, food preferences, taste sensitivity, weight loss, dietary intake
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


